These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 24779077)

  • 1. [Choice of novel endpoints in clinical trials evaluating the efficiency of drug therapy in patients with pulmonary hypertension].
    Avdeev SN
    Ter Arkh; 2014; 86(3):88-93. PubMed ID: 24779077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pulmonary arterial hypertension in patients with congenital heart disease: current issues and health care situation].
    Kaemmerer H; Gorenflo M; Hoeper M; Huscher D; Ewert P; Pittrow D
    Dtsch Med Wochenschr; 2013 Jun; 138(23):1247-52. PubMed ID: 23720182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exercise as an end-point in pulmonary hypertension trials.
    McCullagh B; Girgis RE
    Int J Clin Pract Suppl; 2010 Jan; (165):4-6. PubMed ID: 19958394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy in pulmonary arterial hypertension: a meta-analysis.
    Bai Y; Sun L; Hu S; Wei Y
    Cardiology; 2011; 120(3):157-65. PubMed ID: 22212696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology.
    Macchia A; Marchioli R; Marfisi R; Scarano M; Levantesi G; Tavazzi L; Tognoni G
    Am Heart J; 2007 Jun; 153(6):1037-47. PubMed ID: 17540207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan for the treatment of adult pulmonary hypertension.
    Dwyer N; Kilpatrick D
    Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension.
    Nickel N; Golpon H; Greer M; Knudsen L; Olsson K; Westerkamp V; Welte T; Hoeper MM
    Eur Respir J; 2012 Mar; 39(3):589-96. PubMed ID: 21885392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy in pulmonary arterial hypertension.
    Channick RN
    Am J Cardiol; 2013 Apr; 111(8 Suppl):16C-20C. PubMed ID: 23558025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pulmonary arterial hypertension in childhood].
    Douwes JM; van Loon RL; Roothooft MT; Berger RM
    Ned Tijdschr Geneeskd; 2011; 155(49):A3901. PubMed ID: 22166180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study.
    Deaño RC; Glassner-Kolmin C; Rubenfire M; Frost A; Visovatti S; McLaughlin VV; Gomberg-Maitland M
    JAMA Intern Med; 2013 May; 173(10):887-93. PubMed ID: 23568223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of dyspnea in advanced pulmonary arterial hypertension.
    Sajkov D; Petrovsky N; Palange P
    Curr Opin Support Palliat Care; 2010 Jun; 4(2):76-84. PubMed ID: 20407377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current therapy of pulmonary hypertension.
    Baumhäkel M; Cremers B; Böhm M
    Herz; 2005 Jun; 30(4):303-10. PubMed ID: 15965807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
    McLaughlin VV
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endpoints in pulmonary arterial hypertension: the role of clinical worsening.
    Peacock A; Keogh A; Humbert M
    Curr Opin Pulm Med; 2010 May; 16 Suppl 1():S1-9. PubMed ID: 20375659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension.
    Yao A
    J Cardiol; 2012 Nov; 60(5):344-9. PubMed ID: 23068290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Endothelin receptor antagonist bosentan. Breakthrough in the treatment of pulmonary hypertension].
    MMW Fortschr Med; 2004 Dec; 146(50):72-3. PubMed ID: 15666438
    [No Abstract]   [Full Text] [Related]  

  • 17. Six-minute walk distance as parameter of functional outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.
    Reesink HJ; van der Plas MN; Verhey NE; van Steenwijk RP; Kloek JJ; Bresser P
    J Thorac Cardiovasc Surg; 2007 Feb; 133(2):510-6. PubMed ID: 17258590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
    Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ
    Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy improves exercise capacity and reduces risk of clinical worsening in patients with pulmonary arterial hypertension: a meta-analysis.
    Zhu B; Wang L; Sun L; Cao R
    J Cardiovasc Pharmacol; 2012 Oct; 60(4):342-6. PubMed ID: 22691882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.
    McLaughlin VV; Hoeper MM; Channick RN; Chin KM; Delcroix M; Gaine S; Ghofrani HA; Jansa P; Lang IM; Mehta S; Pulido T; Sastry BKS; Simonneau G; Sitbon O; Souza R; Torbicki A; Tapson VF; Perchenet L; Preiss R; Verweij P; Rubin LJ; Galiè N
    J Am Coll Cardiol; 2018 Feb; 71(7):752-763. PubMed ID: 29447737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.